Semaglutide Reduced Adiposity, Insulin Resistance in HIV Lipohypertrophy; Durability Explored
Durability of Semaglutide Effects After Treatment Discontinuation in HIV-Associated Lipohypertrophy: A Randomized, Double-Blind, Placebo-Controlled Phase 2b Clinical Trial
Abstract
Semaglutide previously cut adiposity and insulin resistance in HIV-associated lipohypertrophy. An ongoing Phase 2b RCT investigates if these benefits persist post-discontinuation.
TitrateLab articles covering Semaglutide
Written by TitrateLab, separately from the study summarized above.
